- Home
- MAIA vs TPST Comparison
MAIA vs TPST Comparison
Compare MAIA & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- TPST
- Stock Information
- Founded
- MAIA 2018
- TPST 2011
- Country
- MAIA United States
- TPST United States
- Employees
- MAIA N/A
- TPST N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- TPST Health Care
- Exchange
- MAIA Nasdaq
- TPST Nasdaq
- Market Cap
- MAIA 44.9M
- TPST 45.5M
- IPO Year
- MAIA 2022
- TPST N/A
- Fundamental
- Price
- MAIA $1.11
- TPST $9.60
- Analyst Decision
- MAIA
- TPST Hold
- Analyst Count
- MAIA 0
- TPST 3
- Target Price
- MAIA N/A
- TPST $30.00
- AVG Volume (30 Days)
- MAIA 742.2K
- TPST 40.4K
- Earning Date
- MAIA 11-07-2025
- TPST 11-05-2025
- Dividend Yield
- MAIA N/A
- TPST N/A
- EPS Growth
- MAIA N/A
- TPST N/A
- EPS
- MAIA N/A
- TPST N/A
- Revenue
- MAIA N/A
- TPST N/A
- Revenue This Year
- MAIA N/A
- TPST N/A
- Revenue Next Year
- MAIA N/A
- TPST N/A
- P/E Ratio
- MAIA N/A
- TPST N/A
- Revenue Growth
- MAIA N/A
- TPST N/A
- 52 Week Low
- MAIA $1.05
- TPST $5.35
- 52 Week High
- MAIA $3.48
- TPST $15.08
- Technical
- Relative Strength Index (RSI)
- MAIA 34.52
- TPST 42.94
- Support Level
- MAIA $1.05
- TPST $9.12
- Resistance Level
- MAIA $1.35
- TPST $10.25
- Average True Range (ATR)
- MAIA 0.10
- TPST 0.55
- MACD
- MAIA -0.03
- TPST -0.15
- Stochastic Oscillator
- MAIA 12.85
- TPST 23.63
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.